{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:40:05Z","timestamp":1788090005512,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intraocular inflammation (IOI) is a rare but potentially sight\u2010threatening complication that can occur after intravitreal anti\u2010vascular endothelial growth factor (anti\u2010VEGF) injections. This adverse event has been under scrutiny in recent years due to an increased incidence, particularly with some of the newer anti\u2010VEGF agents, such as Brolucizumab. Faricimab is a new anti\u2010VEGF medication that has been approved by the United States Food and Drug Administration. As it is relatively new on the market, long\u2010term safety data is still being collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective case series of 8 eyes in 5 patients with IOI that occurred after faricimab intravitreal injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients were diagnosed with significant uveitis with anterior vitreous involvement and 4 out of the 5 patients presented subacutely with high intraocular pressure while the remaining patient presented acutely within 4\u2009days following IVT with normal intraocular pressure. The patients received, on average, 4.875 faricimab injections prior to development of IOI and the inflammation resolved in all patients following cessation of faricimab injections and initiation of oral and topical non\u2010steroidal anti\u2010inflammatory agents and topical steroids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Non\u2010infectious hypertensive uveitis can occur subacutely after intravitreal faricimab injections. It is imperative that intraocular pressure is promptly managed to reduce the risk of permanent glaucomatous damage. As all our patients presented with anterior vitreous involvement, it is also practical that such cases of IOI are not mistaken for infectious exogenous endophthalmitis to avoid unnecessary treatment with intravitreal antibiotics and surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ceo.70058","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:16:47Z","timestamp":1769231807000},"page":"507-513","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series"],"prefix":"10.1111","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7943-1257","authenticated-orcid":false,"given":"Yunhua","family":"Loo","sequence":"first","affiliation":[{"name":"Singapore National Eye Centre  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Lim","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton Cher Yong","family":"Chew","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita Sook Yee","family":"Chan","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaan","family":"Wiryasaputra","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000486145"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.01.029"},{"key":"e_1_2_12_7_1","unstructured":"VABYSMO \u201cVABYSMO (Faricimab\u2010SVOA) | Safety \u201d2023 https:\/\/www.vabysmo\u2010hcp.com\/safety.html."},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051413"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(85)34001-0"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00307-7"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.03.057"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420930863"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.03.035"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S405994"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02553-5"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000154"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.3828"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2361834"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05353-3"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfae046"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6431694"},{"issue":"3","key":"e_1_2_12_23_1","first-page":"44","article-title":"Mechanisms of Hypersensitivity Reactions Induced by Drugs","volume":"90","author":"Fabrizio F.","year":"2019","journal-title":"Acta Biomedica Atenei Parmensis"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2015.1090004"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.5650"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/24741264251332515"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.08.008"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512090"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.70058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ceo.70058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.70058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:48:42Z","timestamp":1780541322000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ceo.70058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/ceo.70058"],"URL":"https:\/\/doi.org\/10.1111\/ceo.70058","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}